Author response for "Rescue of chemorefractory classical Hodgkin lymphoma with Nivolumab and autologous stem‐cell transplantation: real‐life experience"

2020 ◽  
Author(s):  
Valeria Buccheri ◽  
Giancarlo Fatobene ◽  
Fernanda Maria Santos ◽  
Rodrigo Dolphine Velaques ◽  
Marcelo Bellesso ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Life Experience ◽  
Real Life ◽  
Author Response ◽  
Classical Hodgkin Lymphoma

Rescue of chemorefractory classical Hodgkin lymphoma with Nivolumab and autologous stem‐cell transplantation: real‐life experience

2020 ◽  
Author(s):  
Valeria Buccheri ◽  
Giancarlo Fatobene ◽  
Fernanda Maria Santos ◽  
Rodrigo Dolphine Velaques ◽  
Marcelo Bellesso ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Life Experience ◽  
Real Life ◽  
Classical Hodgkin Lymphoma

scholarly journals Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

2018 ◽  
Vol 49 (4) ◽  
pp. 228-233
Author(s):  
Monika Długosz-Danecka ◽  
Michał Szymczyk ◽  
Joanna Fischer ◽  
Anna Łojko-Dankowska ◽  
Justyna Rybka ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Life Experience ◽  
Remission Rate ◽  
Real Life ◽  
Brentuximab Vedotin ◽  
Classical Hodgkin Lymphoma

AbstractAimPolish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure.BackgroundDespite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile.Materials and methodsRetrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.ResultsAfter six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation.ConclusionNivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit.

Reassessment of risk factors and long‐term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma

2019 ◽  
Vol 37 (3) ◽  
pp. 310-313
Author(s):  
Giancarlo Fatobene ◽  
Camila da Cruz Gouveia Linardi ◽  
Frederico Moreira ◽  
Gabriela Matos Falcão Targueta ◽  
Fernanda Maria Santos ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Long Term Results ◽  
Classical Hodgkin Lymphoma
Sign in / Sign up

Export Citation Format

Share Document